MOTS-c (mitochondrial open reading frame of the 12S rRNA type-c) sits in an unusual corner of the peptide literature. It is not a conventional nuclear-encoded hormone analogue. It is a short peptide translated from a small open reading frame inside mitochondrial 12S rRNA, first characterised in 2015, and it has since accumulated a preclinical metabolic dataset that is more coherent than most research-chemical peptides — and a human evidence base that is still largely observational.

This piece is a research briefing, not a protocol. MOTS-c is not a licensed medicine in the United Kingdom. Nothing here is consumption, dosing, or self-administration advice. Research-use-only framing applies throughout.

1. What MOTS-c is

Lee and colleagues at the University of Southern California reported MOTS-c in Cell Metabolism in 2015 as a 16-residue peptide (MRWQEMGYIFYPRKLR) encoded by mitochondrial DNA. Unlike most bioactive peptides discussed on this site, its primary sequence is not derived from a nuclear gene and then processed in the secretory pathway. It is a mitochondrial-derived peptide (MDP), part of a small family that also includes humanin and the SHLPs.

In cultured cells and in mice, MOTS-c is detectable in plasma and in metabolically active tissues. Subsequent work showed that under metabolic stress the peptide can translocate from mitochondria into the nucleus, where it interacts with nuclear transcription programmes rather than acting solely as a circulating hormone. That dual localisation is the mechanistic feature that distinguishes MOTS-c from conventional receptor-ligand peptides.

A later receptor-level paper identified folate receptor α (FOLR1) as a cell-surface binding partner that can mediate at least some MOTS-c actions. That finding is mechanistically useful and still early: FOLR1 biology is well described in other contexts, but the MOTS-c–FOLR1 axis has not been mapped in large human studies.

Factually, then, MOTS-c is a short mitochondrial-encoded peptide with documented cell-autonomous and endocrine-like activity in experimental systems. It is not a growth-hormone secretagogue, not a GLP-1 analogue, and not a licensed metabolic drug.

2. Mechanism, as currently understood

The 2015 discovery paper placed MOTS-c in one-carbon and folate metabolism and downstream of AMP-activated protein kinase (AMPK). In skeletal-muscle models, MOTS-c treatment increased AICAR levels, activated AMPK, and improved insulin-stimulated glucose disposal. Those observations are internally consistent with an exercise-mimetic or metabolic-stress signal, which is how the peptide is usually discussed in the secondary literature.

Kim et al. (2018) then showed nuclear translocation under metabolic stress, with MOTS-c binding antioxidant-response elements and regulating a stress-responsive transcriptional programme. Reynolds et al. (2021) reported that MOTS-c rises after exercise in humans and that late-life MOTS-c treatment improved physical performance in aged mice. Together these papers sketch a model in which MOTS-c is both an exercise-inducible circulating signal and a mitochondrion-to-nucleus messenger.

That model is still a sketch. Key uncertainties: circulating MOTS-c assay validity; relative contribution of FOLR1 versus AMPK/nuclear routes in humans; incomplete dose–exposure translation from mouse work.

Peptide Data therefore treats the mechanism as plausible and multiply replicated in rodents and cells, not established as a human pharmacology.

3. Evidence grade

Grade: limited. Preclinical package is stronger than anecdotal research-chemical peptides. Human package is observational plus an exercise-induced endogenous rise (Reynolds 2021), not a test of exogenous peptide. No large peer-reviewed randomised interventional trial. Do not inflate toward moderate/strong.

4. What the mouse data do and do not support

Supports: improved glucose tolerance and reduced weight gain in high-fat-diet mice; better physical performance in aged mice in Reynolds; AMPK activation and stress-responsive nuclear gene regulation in cells. Does not support: exercise replacement in humans; treatment of insulin resistance or type 2 diabetes; equivalence of commercial vials to academic material.

5. UK regulatory position

No MHRA marketing authorisation. Not a UK POM with an approved indication. Not scheduled under the Misuse of Drugs Act 1971. Grey-area research peptide: supply as a medicine engages the Human Medicines Regulations 2012 and Medicines Act 1968. MHRA 2026 research-peptide labelling guidance applies. Research use only; no consumption advice; no human-use protocols.

6. Analytical and vendor caveats

Short mitochondrial peptides are a hostile analytical target. Require batch-specific ISO-lab CoA, intact-mass confirmation of the 16-residue sequence and salt form, plus endotoxin/residual-solvent data for cell or in-vivo systems. Generic purity >98% without method is insufficient. Peptide Biosciences affiliation, where present, must be disclosed and does not change the evidence grade.

7. Related mitochondrial peptides

Elamipretide (SS-31) is a distinct cardiolipin-binding tetrapeptide with a more advanced clinical programme. Not an analogue of MOTS-c. Humanin and SHLPs share the MDP class; human evidence likewise limited; none MHRA-licensed.

8. Bottom line

Mouse AMPK-linked metabolic phenotype is real and replicated. Human interventional data are not. MHRA has not authorised MOTS-c as a medicine. Evidence grade stays limited.

This article is AI-researched and editorially reviewed. It is provided for research and educational purposes only and is not medical advice. Research peptides are not licensed for human consumption in the UK.